Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Kim E. Zerba"'
Autor:
Ariella Sasson, Joseph D. Szustakowski, Ryan Golhar, William J. Geese, Stefan Kirov, Han Chang, George Green, Sujaya Srinivasan, Danielle Greenawalt, Kim E. Zerba
Publikováno v:
Molecular Diagnosis & Therapy
Introduction Tumor mutational burden (TMB) has emerged as a clinically relevant biomarker that may be associated with immune checkpoint inhibitor efficacy. Standardization of TMB measurement is essential for implementing diagnostic tools to guide tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662517ad8b4a4f52e16b9bfb813cea93
https://doi.org/10.1007/s40291-019-00408-y
https://doi.org/10.1007/s40291-019-00408-y
Autor:
Martin Gutierrez, Mark M. Awad, Joseph D. Szustakowski, Suresh S. Ramalingam, Jason Chesney, Justin F. Gainor, Neal Ready, Kim E. Zerba, Pavan S. Reddy, Ian Rabinowitz, Brian Lestini, Mihaela Mates, Xuemei Li, Martin Reck, James Michael Orcutt, George Green, Julie R. Brahmer, David R. Spigel, William J. Geese, Matthew D. Hellmann, Gregory A. Otterson, Kenneth J. O'Byrne, Jacques Jolivet, Wenhua Hu, Luis Paz-Ares, Leora Horn, Han Chang, Hossein Borghaei
Publikováno v:
Journal of Clinical Oncology
PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non–small-cell lung cancer (NSCLC). We assessed the association of eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24ea6ae4a4189dd4a5b12cd785da56cb
http://europepmc.org/articles/PMC6494267
http://europepmc.org/articles/PMC6494267
Autor:
Virginia Burns, Sucha Sudarsanam, Cory Batenchuk, Vladislav Chizhevsky, Kim E. Zerba, Maher Albitar, Chelsea Jin
Publikováno v:
Journal of Clinical Pathology
AimsAt the time of analysis, two widely used, drug-specific, tumour-cell programmed death ligand 1 (PD-L1) assays were approved by the US Food and Drug Administration for anti-PD-1 therapies: the Dako PD-L1 immunohistochemistry (IHC) 28-8 pharmDx ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5860e023c5dc33392ec684908a408086
http://europepmc.org/articles/PMC6287558
http://europepmc.org/articles/PMC6287558
Publikováno v:
Journal of Applied Statistics. 46:272-285
Anti-tumor treatment outcomes in mouse experiments can be challenging to interpret and communicate accurately. In reporting these experiments, rigorous statistical considerations are commonly absent, although statistical applications have been propos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::745508ac7d9f6ec6cc2e67e6a1d8ecca
https://doi.org/10.1080/02664763.2018.1477925
https://doi.org/10.1080/02664763.2018.1477925
Autor:
Joseph D. Szustakowski, William J. Geese, Ryan Golhar, Kim E. Zerba, Stefan Kirov, Danielle Greenawalt, Sujaya Srinivasan, Han Chang, Ariella Sasson, George Green
IntroductionTumor mutational burden (TMB) has emerged as a clinically relevant biomarker that may be associated with immune checkpoint inhibitor efficacy. Standardization of TMB measurement is essential for implementing diagnostic tools to guide trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f57199f755bfa45a8e94513c35e4c59b
https://doi.org/10.1101/626143
https://doi.org/10.1101/626143
Autor:
V. Chizhevsky, Gabriel S Krigsfeld, Kim E. Zerba, James William White, James Novotny, J.W. Ragheb
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 104:236-237
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30b2a74c1eb72794cf2f53b88c22657f
https://doi.org/10.1016/j.ijrobp.2019.01.026
https://doi.org/10.1016/j.ijrobp.2019.01.026
Autor:
Neeraj Adya, Marian Navratil, Scott Ely, Zhenhao Qi, Kim E. Zerba, Péter Szabó, Gillian L Dalgliesh, Robin Edwards, James Cooley, James Lu
Publikováno v:
Journal of Clinical Oncology. 37:2593-2593
2593 Background: A multiparameter tumor inflammation assay based on gene expression profiling (TIA-GEP) can extend the utility of IHC to interrogate the tumor microenvironment (TME). Using CD8 expression assessed by IHC (CD8-IHC) as a surrogate for i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51a005cbdbdfbc630579bc4e1e13de20
https://doi.org/10.1200/jco.2019.37.15_suppl.2593
https://doi.org/10.1200/jco.2019.37.15_suppl.2593
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 104:236
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd7842ca44779037c05f95adc4ec836d
https://doi.org/10.1016/j.ijrobp.2019.01.025
https://doi.org/10.1016/j.ijrobp.2019.01.025
Autor:
Vladislav Chizhevsky, Kim E. Zerba, Emily A. Prince, Josette William Ragheb, Gabriel S Krigsfeld, James William White
Publikováno v:
Journal of Clinical Oncology. 37:151-151
151 Background: A number of programmed death ligand 1 (PD-L1) IHC diagnostic tests have been approved by the FDA to guide treatment with programmed death-1/PD-L1 inhibitors. We evaluated PD-L1 assay utilization and concordance across all tumor types,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1afe42ae39e0c090a33f78260eb617d3
https://doi.org/10.1200/jco.2019.37.8_suppl.151
https://doi.org/10.1200/jco.2019.37.8_suppl.151
Autor:
Emily A. Prince, Kim E. Zerba, James William White, Josette William Ragheb, James Novotny, Vladislav Chizhevsky, Gabriel S Krigsfeld
Publikováno v:
Journal of Clinical Oncology. 37:447-447
447 Background: Programmed death-1/programmed death ligand 1 (PD-1/PD-L1) inhibitors are FDA-approved for urothelial carcinoma (UC) among other tumor types. PD-L1 immunohistochemistry (IHC) testing for UC has evolved with several diagnostic approvals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::487afbf569608d8ec5fd700a45336e20
https://doi.org/10.1200/jco.2019.37.7_suppl.447
https://doi.org/10.1200/jco.2019.37.7_suppl.447